Recurrent ATRT
Showing 1 - 25 of 7,749
Rhabdoid Tumors Cellular Architecture by Single-cell Analyses
Recruiting
- ATRT
- analyzes in singles cells
-
Paris, FranceInstitut Curie
Apr 4, 2022
Brain Tumor Recurrent Trial in Houston (Methotrexate, Etoposide, Ommaya Reservoir)
Recruiting
- Brain Tumor Recurrent
- Methotrexate
- +2 more
-
Houston, TexasUTHealth & Children's Memorial Hermann Hospital
Aug 17, 2022
Neuroblastoma, CNS Tumor, Sarcoma Trial in Columbus (Cabozantinib)
Recruiting
- Neuroblastoma
- +2 more
-
Columbus, OhioNationwide Children's Hospital
Dec 20, 2022
Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor Trial in United States (drug, procedure, radiation)
Recruiting
- Malignant Rhabdoid Tumor
- Atypical Teratoid Rhabdoid Tumor
- alisertib
- +9 more
-
Los Angeles, California
- +10 more
Aug 1, 2022
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma Trial (Atezolizumab, Tiragolumab)
Recruiting
- Atypical Teratoid/Rhabdoid Tumor
- +17 more
- Atezolizumab
- +7 more
-
Birmingham, Alabama
- +19 more
Feb 2, 2023
Exploration of Locally Recurrent Colorectal Cancer
Recruiting
- Locally Recurrent Colorectal Cancer
- salvage surgery
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences & Peking Un
Oct 28, 2023
Factors Associated With Recurrent Falls in Stroke Patients
Completed
- Fall
- Stroke
- Fall evaluation
-
İzmir, TurkeyUniversity of Health Sciences Turkey
Sep 25, 2023
Cadonilimab in Recurrent or Metastatic Cervical Cancer
Not yet recruiting
- Recurrent or Metastatic Cervical Cancer
- (no location specified)
Nov 23, 2023
Benign Paroxysmal Positional Vertigo Trial in Istanbul (Cervical VEMP testing)
Recruiting
- Benign Paroxysmal Positional Vertigo
- Cervical VEMP testing
-
İstanbul, TurkeyHaseki Training and Research Hospital
Jun 19, 2023
Colon Cancer Trial in Qingdao (Chimeric antigen receptor T cell preparation targeting GCC)
Recruiting
- Colon Cancer
- Chimeric antigen receptor T cell preparation targeting GCC
-
Qingdao, Shandong, ChinaThe Affiliated Hospital of Qingdao University
May 16, 2023
Potential Chemoprevention Drugs in Recurrent Hepatocellular
Recruiting
- Hepatocellular Carcinoma Recurrent
- Surgery
- No intervention for research purpose
-
Taichung, TaiwanChina Medical University Hospital, Department of Surgery
Aug 5, 2023
High Risk Prostate Carcinoma Trial in Gyeonggi-do, Seoul, Soeul ([F-18]Florastamin)
Recruiting
- High Risk Prostate Carcinoma
-
Gyeonggi-do, Korea, Republic of
- +5 more
Jun 29, 2023
Hepatic Encephalopathy Trial in Hangzhou (Fecal Microbiota Transplantation)
Active, not recruiting
- Hepatic Encephalopathy
- Fecal Microbiota Transplantation
-
Hangzhou, Zhejiang, ChinaShulan (Hangzhou) Hospital
Dec 29, 2022
Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Zanzalintinib
- +2 more
- (no location specified)
Oct 9, 2023
Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)
Not yet recruiting
- Ovarian Cancer Recurrent
- Fluzopril Combined With Apatinib
- (no location specified)
Oct 22, 2023
Hepatocellular Carcinoma Trial in United States (AZD5851)
Not yet recruiting
- Hepatocellular Carcinoma
- AZD5851
-
Duarte, California
- +9 more
Oct 12, 2023
Breast Cancer Trial (SHR-A1811, Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel)
Not yet recruiting
- Breast Cancer
- (no location specified)
Apr 3, 2023
The International Centre for Recurrent Head and Neck Cancer
Not yet recruiting
- Head Cancer Neck
- (no location specified)
May 30, 2023
Relapsed Ovarian Cancer Trial in Hangzhou (Secondary cytoreduction, Chemotherapy)
Recruiting
- Relapsed Ovarian Cancer
- Secondary cytoreduction
- Chemotherapy
-
Hangzhou, Zhejiang, ChinaWomen's Hospital, Zhejiang University School of Medicine
Nov 4, 2022
Glioblastoma Multiforme Trial in Shijia Zhuang (TMZ)
Recruiting
- Glioblastoma Multiforme
-
Shijia Zhuang, Hebei, Chinathe Second Hospital of HeBei Medical University
Oct 18, 2022
Bladder Cancer Trial (Multi4)
Not yet recruiting
- Bladder Cancer
- Multi4
- (no location specified)
Nov 14, 2023